Last reviewed · How we verify
Multiple Daily Injections of Insulin
Multiple daily insulin injections replace or supplement the body's own insulin production to regulate blood glucose levels.
Multiple daily insulin injections replace or supplement the body's own insulin production to regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).
At a glance
| Generic name | Multiple Daily Injections of Insulin |
|---|---|
| Also known as | Basal bolus injections of insulin |
| Sponsor | DreaMed Diabetes |
| Drug class | Insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin is a hormone that facilitates glucose uptake into cells and promotes glycogen synthesis, lowering blood glucose. Multiple daily injection (MDI) regimens typically combine long-acting basal insulin with rapid-acting bolus insulin at meals to mimic physiological insulin secretion patterns. This approach allows flexible dosing and meal-time coverage for improved glycemic control in diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus (when oral agents are insufficient)
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectiveness of AID Treatment (NA)
- Intervention for Children With Type 1 Diabetes Targeting Gut Microbes (NA)
- Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus (NA)
- Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes (NA)
- Bionic Pancreas in CFRD (PHASE3)
- FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) (PHASE2)
- To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. (NA)
- Next Generation Advanced Insulin Delivery System in Adults With Diabetes and Advanced Renal Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Multiple Daily Injections of Insulin CI brief — competitive landscape report
- Multiple Daily Injections of Insulin updates RSS · CI watch RSS
- DreaMed Diabetes portfolio CI